Mexiletine

Mexiletine is an oral Class IB antiarrhythmic agent used for the chronic management of ventricular arrhythmias in dogs, providing an important therapeutic option for patients with persistent rhythm disturbances originating from the ventricles. As a sodium channel blocker structurally related to lidocaine, mexiletine offers the advantage of oral administration for long-term outpatient therapy, making it the practical choice for dogs requiring ongoing ventricular arrhythmia suppression. The medication is particularly valuable in managing dogs with arrhythmogenic right ventricular cardiomyopathy, a condition commonly affecting Boxers, as well as ventricular arrhythmias associated with other forms of structural heart disease. Originally developed for human cardiac conditions, mexiletine has become an established component of the veterinary cardiology armamentarium.

The mechanism of action of mexiletine involves selective blockade of sodium channels in cardiac tissue, specifically affecting the fast sodium channels responsible for the rapid depolarization phase of the ventricular action potential. Like lidocaine, mexiletine exhibits state-dependent binding, preferentially interacting with sodium channels in their inactive state. This property allows the drug to selectively suppress abnormally firing ventricular cells while having minimal effects on normal cardiac tissue at therapeutic doses. Mexiletine shortens the action potential duration and effective refractory period in ventricular muscle, which helps prevent and terminate ventricular arrhythmias. The drug has minimal effects on sinoatrial node function, atrioventricular conduction, and atrial tissue, making it specific for ventricular rhythm disorders.

Mexiletine is available in capsule and tablet form for oral administration, allowing for convenient home administration by pet owners. The medication is typically given two to three times daily due to its pharmacokinetic profile in dogs. Various strengths are available, permitting dose adjustment across the range of canine body sizes. The capsules and tablets are not flavored, so dogs may require the medication to be hidden in food or treats for easier administration. Some dogs may experience gastrointestinal upset with mexiletine, and administration with food can help minimize this side effect.

The safety profile of mexiletine in dogs is generally acceptable when used at appropriate doses under veterinary supervision, though the medication requires regular monitoring due to its effects on cardiac conduction and potential for adverse reactions. The veterinarian will establish an appropriate dosing regimen and monitoring schedule based on the individual patient's arrhythmia severity and overall health status. Electrocardiographic evaluation helps assess the effectiveness of arrhythmia control and detect any adverse effects on cardiac conduction. When used appropriately, mexiletine provides effective long-term management of ventricular arrhythmias, improving quality of life and potentially reducing the risk of sudden death in affected dogs.

The primary indication for mexiletine in dogs is the chronic oral management of ventricular arrhythmias, including sustained or nonsustained ventricular tachycardia and frequent ventricular premature complexes. These rhythm disturbances originate from abnormal electrical activity in the ventricles and can range from benign to life-threatening depending on their frequency, complexity, and underlying cause. Mexiletine provides effective suppression of ventricular ectopy for dogs requiring long-term antiarrhythmic therapy that extends beyond the acute hospital setting. The oral formulation makes home administration practical, allowing owners to manage their dog's cardiac condition as part of daily care.

Arrhythmogenic right ventricular cardiomyopathy represents one of the most important indications for mexiletine therapy in dogs, particularly in Boxers who are highly predisposed to this condition. This disease involves progressive replacement of normal heart muscle with fatty or fibrous tissue, creating substrates for dangerous ventricular arrhythmias. Affected dogs may experience syncope or sudden death due to ventricular tachycardia. Mexiletine, often used in combination with a beta-blocker such as sotalol, helps suppress these arrhythmias and may improve survival in affected dogs. The combination approach takes advantage of complementary antiarrhythmic mechanisms for more effective arrhythmia control.

Doberman Pinschers and other large breeds with dilated cardiomyopathy commonly develop ventricular arrhythmias as their disease progresses. These arrhythmias can contribute to clinical decline and carry risk for sudden death. Mexiletine may be prescribed as part of the comprehensive management of these patients, working alongside other cardiac medications such as pimobendan and diuretics. The decision to initiate antiarrhythmic therapy depends on the frequency and severity of the arrhythmias as determined by electrocardiographic monitoring, including Holter monitoring that records heart rhythm over 24 hours or longer.

Mexiletine serves as oral continuation therapy for dogs initially stabilized with intravenous lidocaine for acute ventricular arrhythmias. Because lidocaine and mexiletine share the same Class IB antiarrhythmic mechanism, transitioning from intravenous lidocaine to oral mexiletine provides continuity of antiarrhythmic effect. This transition is commonly performed for dogs with ventricular arrhythmias secondary to conditions such as gastric dilatation-volvulus, myocarditis, or other acute illnesses once the patient is stable enough for oral medication.

When selecting mexiletine for ventricular arrhythmia management, veterinary cardiologists consider several factors including the specific arrhythmia characteristics, underlying cardiac disease, patient tolerance, and potential for drug interactions. Mexiletine is often most effective when combined with other antiarrhythmic agents, particularly beta-blockers, rather than used as monotherapy. This combination approach allows lower doses of each drug while achieving superior arrhythmia suppression. The choice between mexiletine and alternative antiarrhythmics such as sotalol depends on the individual patient's response, side effect profile, and specific clinical circumstances.

Dosing of mexiletine in dogs requires individualized determination by the prescribing veterinarian or veterinary cardiologist, as appropriate doses vary based on the severity and type of arrhythmia, the presence of underlying cardiac disease, individual patient factors, and response to therapy. The veterinarian will determine the starting dose after comprehensive cardiac evaluation including electrocardiography and often echocardiography. Holter monitoring, which records heart rhythm continuously over 24 hours or more, provides valuable information about arrhythmia frequency and severity to guide treatment decisions. Accurate body weight measurement is essential for dose calculation.

The typical dosing range for mexiletine in dogs is 5 to 10 milligrams per kilogram of body weight, administered orally two to three times daily. Some dogs may require doses at the higher end of this range for adequate arrhythmia suppression, while others achieve good control at lower doses. Treatment often begins with conservative dosing, with upward titration based on repeat Holter monitoring showing persistent arrhythmias. The goal is to reduce arrhythmia burden sufficiently to decrease clinical signs and reduce the risk of sudden death while minimizing adverse effects. Combination therapy with a beta-blocker often allows use of lower mexiletine doses.

Treatment duration with mexiletine is typically long-term or lifelong for dogs with conditions such as arrhythmogenic right ventricular cardiomyopathy or dilated cardiomyopathy with ventricular arrhythmias. These structural heart diseases and their associated rhythm disturbances require ongoing management rather than short-term treatment. Regular monitoring through periodic electrocardiograms and Holter recordings helps assess the continued effectiveness of therapy and guides dose adjustments as the disease may progress over time. The veterinarian will establish an appropriate monitoring schedule based on the individual patient's condition.

Mexiletine should be administered with food to help reduce the gastrointestinal side effects that can occur with this medication. The capsules or tablets can be given during regular meal times, hidden in food if necessary to facilitate administration. Consistent timing of doses helps maintain stable blood levels for optimal arrhythmia control. If a dog experiences persistent gastrointestinal upset despite administration with food, the veterinarian should be consulted about potential dose adjustment or alternative approaches.

If a dose of mexiletine is missed, it should be given as soon as the owner remembers, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Owners should never give a double dose to compensate for a missed dose, as this increases the risk of toxicity. Because mexiletine is typically given multiple times daily, occasional missed doses may have less impact on arrhythmia control than with once-daily medications, but consistent administration remains important. Owners should contact their veterinarian if multiple doses are missed.

Discontinuation of mexiletine should be discussed with the veterinarian rather than stopped abruptly, particularly in dogs with significant ventricular arrhythmias. Sudden cessation of antiarrhythmic therapy could lead to recurrence of dangerous arrhythmias. If discontinuation is desired due to side effects or other concerns, the veterinarian may recommend gradual dose reduction while monitoring for arrhythmia recurrence. Any changes to the medication regimen should be made under professional guidance.

Mexiletine is generally tolerated by most dogs when administered at appropriate doses under veterinary supervision, though gastrointestinal and neurological side effects occur with sufficient frequency to warrant owner awareness. The adverse effects of mexiletine are related to its actions on sodium channels in both cardiac and non-cardiac tissues. Most dogs receiving mexiletine for ventricular arrhythmias can be maintained on therapy with acceptable side effect profiles when appropriate dosing and administration practices are followed.

The most common side effects of mexiletine in dogs involve the gastrointestinal tract. Nausea, vomiting, and decreased appetite are frequently reported, particularly when therapy is initiated or doses are increased. Administering the medication with food typically helps reduce these effects. Diarrhea may occur in some dogs. These gastrointestinal effects are usually mild and may improve over time as the dog acclimates to the medication. If persistent or severe gastrointestinal upset occurs, the veterinarian may recommend dose reduction or evaluate for alternative causes.

Neurological side effects can occur with mexiletine, reflecting the drug's effects on sodium channels in nervous tissue. Dogs may exhibit tremors, ataxia or unsteady gait, apparent dizziness, or changes in behavior. These signs are more common at higher doses and may indicate that blood levels are approaching or exceeding the therapeutic range. Lethargy or decreased activity may be observed. If neurological signs develop, the veterinarian should be contacted to evaluate whether dose adjustment is needed. In most cases, reducing the dose alleviates neurological adverse effects.

Cardiovascular side effects are possible with mexiletine therapy. The drug can affect cardiac conduction, potentially causing bradycardia or conduction abnormalities. Proarrhythmic effects, where the medication paradoxically worsens or creates new arrhythmias, can rarely occur. Hypotension is possible, though less common than with some other cardiovascular medications. Dogs receiving mexiletine should have periodic electrocardiographic monitoring to assess for adverse cardiac effects. New or worsening symptoms such as weakness, collapse, or syncope warrant immediate veterinary evaluation.

Serious adverse effects requiring immediate veterinary attention include severe neurological signs such as seizures or severe disorientation, signs of cardiovascular collapse including profound weakness or loss of consciousness, and severe persistent vomiting that prevents medication administration or leads to dehydration. Allergic reactions are rare but may manifest as facial swelling, hives, or difficulty breathing. Any concerning signs should prompt contact with the veterinary team. The veterinarian will assess whether dose adjustment, temporary discontinuation, or alternative therapy is appropriate based on the nature and severity of adverse effects.

Mexiletine is contraindicated in dogs with known hypersensitivity or allergy to mexiletine or related medications. Cross-reactivity may exist with lidocaine and other amide-type local anesthetics and Class IB antiarrhythmic agents. Dogs that have experienced adverse reactions to lidocaine should be treated with caution, as similar reactions may occur with mexiletine. Any history of previous drug reactions should be communicated to the veterinarian before initiating therapy.

Significant cardiovascular contraindications exist for mexiletine use in dogs. The medication should not be administered to dogs with second-degree or third-degree atrioventricular block unless a pacemaker is in place, as mexiletine can further impair cardiac conduction and worsen heart block. Severe sinus node dysfunction or sick sinus syndrome generally contraindicates mexiletine use due to the risk of profound bradycardia or asystole. Dogs with cardiogenic shock or severe hypotension should not receive mexiletine until stabilized. Caution is required in dogs with any pre-existing conduction abnormalities, as the drug may exacerbate these conditions.

Hepatic dysfunction represents a significant concern for mexiletine therapy. The liver is primarily responsible for metabolizing mexiletine, and dogs with significant liver disease may accumulate the drug to toxic levels. Impaired hepatic function leads to prolonged drug half-life and increased risk of adverse effects. If mexiletine must be used in dogs with liver disease, dose reduction and enhanced monitoring are essential. Baseline liver function should be evaluated before initiating therapy, and periodic monitoring may be advisable during treatment.

Additional conditions requiring caution include severe heart failure, where mexiletine's potential negative inotropic effects may worsen cardiac function. Seizure disorders may be exacerbated by mexiletine's neurological effects. Dogs with significant renal impairment may have altered drug elimination, though the kidney plays a lesser role in mexiletine clearance compared to the liver. Pregnancy and lactation have not been well studied in dogs, and the drug should only be used if benefits clearly outweigh potential risks. Concurrent treatment with other antiarrhythmic medications requires careful consideration due to potential for additive effects on cardiac conduction and increased toxicity risk.

Comprehensive disclosure of all medications, supplements, and over-the-counter products the dog receives is essential before initiating mexiletine therapy. Drug interactions can significantly affect mexiletine's safety and efficacy, and the veterinarian needs complete information to anticipate potential interactions and adjust therapy accordingly. Mexiletine is metabolized by the liver, and drugs affecting hepatic enzyme activity can alter its blood levels and effects.

Significant interactions exist between mexiletine and other cardiovascular medications. Concurrent use with other antiarrhythmic drugs requires careful consideration, as additive effects on cardiac conduction can increase the risk of bradycardia, heart block, or proarrhythmia. The combination of mexiletine with Class IA antiarrhythmics such as procainamide or Class IC agents may produce excessive sodium channel blockade. Beta-blockers are frequently combined with mexiletine intentionally for enhanced arrhythmia suppression, but this combination requires appropriate monitoring. Drugs that prolong the QT interval should be used cautiously with mexiletine. Digoxin interactions are possible, though typically less significant than with some other antiarrhythmics.

Various non-cardiovascular medications can interact with mexiletine through effects on hepatic metabolism. Cimetidine inhibits the liver enzymes that metabolize mexiletine, potentially increasing blood levels and risk of toxicity. Conversely, phenobarbital, rifampin, and other enzyme-inducing drugs may accelerate mexiletine metabolism, potentially reducing its effectiveness. Theophylline metabolism may be affected by mexiletine, requiring attention in dogs receiving both medications. Opioid analgesics may have enhanced effects when combined with mexiletine. Metoclopramide and other drugs affecting gastric emptying can alter mexiletine absorption.

Monitoring and management of drug interactions during mexiletine therapy involve regular veterinary evaluations and appropriate diagnostic testing. Electrocardiographic monitoring helps detect conduction abnormalities that might result from drug interactions. Periodic Holter monitoring assesses ongoing arrhythmia suppression and can reveal whether the current regimen remains effective. Blood work may be recommended to monitor liver function, particularly in dogs receiving multiple medications metabolized hepatically. If signs of drug interactions develop, including neurological symptoms, gastrointestinal upset, or changes in arrhythmia control, the veterinarian should be contacted for evaluation and potential therapy adjustment.

General precautions for mexiletine use in dogs emphasize the importance of accurate dosing and regular veterinary monitoring. The medication should be administered at the prescribed dose and frequency, with attention to consistent timing for optimal blood level maintenance. Doses should be given with food to minimize gastrointestinal side effects. Owners should not adjust doses without veterinary guidance, as both underdosing and overdosing carry risks. Changes in the dog's weight should be reported, as dose adjustments may be needed. Any new symptoms or changes in the dog's condition warrant veterinary consultation.

Breed-specific considerations for mexiletine relate primarily to the underlying cardiac conditions for which it is prescribed. Boxers are particularly predisposed to arrhythmogenic right ventricular cardiomyopathy, making this breed commonly represented among dogs receiving mexiletine therapy. Owners of Boxers should be aware of the signs of this condition and the importance of cardiac screening. Doberman Pinschers frequently develop dilated cardiomyopathy with associated ventricular arrhythmias. German Shepherds may develop ventricular arrhythmias associated with various cardiac conditions. The MDR1 gene mutation affecting herding breeds does not significantly impact mexiletine safety, as it is not a P-glycoprotein substrate.

Environmental and handling precautions for mexiletine focus on safe medication storage and administration in the home environment. The medication should be kept in its original container in a secure location inaccessible to children and other pets. Accidental ingestion of mexiletine by other household members or animals could cause serious adverse effects. The capsules should not be opened or the tablets crushed unless specifically directed by the veterinarian. Hands should be washed after handling the medication.

Monitoring during mexiletine therapy includes regular veterinary examinations with cardiac auscultation and electrocardiography. Holter monitoring provides the most comprehensive assessment of arrhythmia control and is typically performed periodically to evaluate treatment effectiveness. Baseline and periodic blood work helps monitor liver function given the hepatic metabolism of mexiletine. Owners should monitor their dog for signs of adverse effects including gastrointestinal upset, neurological changes, or symptoms suggesting cardiovascular problems such as weakness, exercise intolerance, or syncope.

Special populations requiring additional consideration include geriatric dogs, who may have age-related decreases in liver function affecting mexiletine metabolism. Older dogs may require reduced doses and more frequent monitoring. Dogs with concurrent liver disease need careful dose adjustment and enhanced monitoring. Patients with mild renal impairment generally tolerate mexiletine but should be monitored. Dogs with pre-existing neurological conditions should be observed for exacerbation of symptoms. Working and performance dogs may experience reduced exercise tolerance, which owners should factor into activity planning.

Proper storage of mexiletine capsules or tablets is essential to maintain medication effectiveness throughout the treatment period. The medication should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit, in a dry location protected from excessive moisture. The original container should be used and kept tightly closed to protect the medication from humidity and light exposure. Storage locations near heat sources such as stoves or radiators should be avoided, as should areas prone to temperature fluctuations like bathrooms or vehicles. The medication should not be refrigerated or frozen.

Specific handling requirements for mexiletine include keeping the capsules or tablets intact until administration. Capsules should not be opened, and tablets should not be crushed or split unless specifically directed by the veterinarian, as this may affect drug release characteristics and stability. Expiration dates should be checked regularly, and medication should not be used beyond this date. Signs of capsule or tablet degradation include discoloration, unusual odor, or changes in texture. Any medication showing these signs should be discarded and replaced with a fresh supply.

Safety and disposal considerations for mexiletine emphasize protecting household members and the environment. The medication should be stored in a secure location that children and pets cannot access, as accidental ingestion can cause serious cardiovascular and neurological effects. Child-resistant containers should be used when available. In multi-pet households, particular care should be taken to ensure only the intended patient receives medication. Proper disposal of unused or expired mexiletine should follow FDA guidelines for safe medication disposal. Drug take-back programs offered by pharmacies or community organizations provide the safest disposal option. If no take-back program is available, the medication can be mixed with coffee grounds, dirt, or cat litter in a sealed container for disposal in household trash. Flushing medications is generally not recommended due to environmental concerns.

Most dogs tolerate mexiletine appropriately regardless of breed, with therapeutic response determined primarily by individual arrhythmia characteristics and patient factors rather than breed-specific drug metabolism differences. Mexiletine does not have known breed-specific contraindications based on genetic polymorphisms affecting drug handling. The MDR1 gene mutation found in many herding breeds, which impacts the safety of numerous medications, does not significantly affect mexiletine pharmacology. This allows the medication to be used in Collies, Australian Shepherds, Shetland Sheepdogs, and related breeds without additional MDR1-related concerns.

Certain breeds are predisposed to cardiac conditions for which mexiletine is commonly prescribed, making familiarity with the medication particularly important for owners of these breeds. Boxers are highly susceptible to arrhythmogenic right ventricular cardiomyopathy, with some studies suggesting 40 to 50 percent of the breed may be affected to varying degrees. This disease causes potentially life-threatening ventricular arrhythmias that commonly require long-term management with mexiletine, typically in combination with sotalol or another beta-blocker. Doberman Pinschers are predisposed to dilated cardiomyopathy, which frequently progresses to include ventricular arrhythmias. English Bulldogs and other breeds may develop ventricular arrhythmias associated with various cardiac conditions.

Size considerations affect mexiletine dosing across the range of canine body sizes. Toy and small breed dogs weighing under ten pounds require precise dosing, and available capsule and tablet strengths may need to be modified through compounding pharmacies to achieve accurate doses for very small patients. Standard formulations work well for most medium to large dogs. Giant breed dogs may require larger total doses but should still be dosed according to body weight calculations. Accurate weight measurement is essential regardless of size to ensure appropriate dosing.

Age-related considerations affect mexiletine use across the canine lifespan. Puppies and young dogs rarely require antiarrhythmic therapy with mexiletine. Adult dogs in the prime of life represent the typical patient population, as the cardiac conditions requiring mexiletine often develop during middle age. Geriatric dogs, typically those seven years and older though this varies by breed, may have decreased liver function affecting mexiletine metabolism and clearance. Older patients may require reduced doses or less frequent administration to avoid drug accumulation. Regular monitoring of liver function helps guide appropriate dosing in senior patients.

Lidocaine is the most closely related medication to mexiletine, sharing the same Class IB antiarrhythmic mechanism as a sodium channel blocker. Lidocaine is administered intravenously for acute ventricular arrhythmias, while mexiletine provides oral continuation therapy for long-term management. The two drugs are frequently used in sequence, with lidocaine controlling arrhythmias acutely and mexiletine taking over for chronic suppression. Tocainide was another oral Class IB agent but is no longer commonly available. Phenytoin has Class IB antiarrhythmic properties and may occasionally be considered for specific indications.

Sotalol represents the most commonly used alternative or combination medication for ventricular arrhythmias in dogs. Sotalol combines beta-blocking properties with Class III antiarrhythmic effects, providing a different mechanism of action that complements mexiletine. The combination of mexiletine and sotalol is frequently used for dogs with arrhythmogenic right ventricular cardiomyopathy, as the two drugs work through complementary pathways to provide superior arrhythmia suppression compared to either agent alone. Other beta-blockers such as atenolol or propranolol may be combined with mexiletine when sotalol is not appropriate. Procainamide is a Class IA antiarrhythmic that provides an alternative mechanism for ventricular arrhythmia management. Amiodarone is a Class III agent used for refractory arrhythmias.

Complementary therapies and supportive care often accompany mexiletine therapy in dogs with cardiac disease. Pimobendan is commonly prescribed for dogs with structural heart disease and systolic dysfunction, working alongside antiarrhythmic medications to support cardiac function. Diuretics such as furosemide help manage fluid accumulation in dogs with congestive heart failure. ACE inhibitors including enalapril and benazepril provide neurohormonal modulation and cardiovascular benefits. Omega-3 fatty acid supplementation may offer mild antiarrhythmic properties as a supportive measure. Regular exercise restriction may be recommended for dogs with significant arrhythmias. All medication changes or additions should be made under veterinary guidance to ensure appropriate monitoring and avoid harmful interactions.